Whose Treatment Plan Is It, Anyway? How Clinic Incentives Can Shape Your IVF Path

When you walk into a fertility clinic, you reasonably expect that every option available to you will be laid on the table. You expect that the protocol recommended will be the one best suited to your biology, your history, and your goals. In many cases, that expectation is met. But the fertility industry in the United States operates within a set of structural realities—financial models, institutional efficiencies, and performance metrics—that can, sometimes without anyone intending harm, influence which paths are presented and which remain unmentioned.

This is not an accusation. It is an invitation to ask harder questions.

The Business Architecture of a Fertility Clinic

Most reproductive endocrinology practices in the US are structured as private businesses. Some are independent; many are now part of larger private equity-backed networks that have consolidated rapidly over the past decade. This consolidation has introduced a layer of financial accountability that did not exist in the same form when fertility medicine was primarily practiced by smaller, physician-owned clinics.

Revenue in these settings is generated through cycles—stimulation cycles, retrieval cycles, transfer cycles. Each phase carries a fee. Add-on services, such as preimplantation genetic testing (PGT), endometrial receptivity analysis, or extended embryo culture, generate additional revenue. This is not inherently problematic; these services often carry genuine clinical value. But it does mean that the economic incentives of a clinic are not always perfectly aligned with the most conservative, least interventional path a patient might reasonably pursue.

A 2020 analysis published in Fertility and Sterility noted that the uptake of add-on services in US fertility clinics frequently outpaces the evidence base supporting them. Patients, eager for any advantage and often emotionally vulnerable, may accept recommended additions without fully understanding whether the supporting data applies to their specific situation.

Standardized Protocols and the Individual Patient

Fertility clinics develop standardized protocols for efficiency and safety—both legitimate aims. A clinic that treats hundreds of patients simultaneously cannot build an entirely bespoke treatment plan for each one from the ground up. Protocols based on aggregate outcomes are a reasonable starting point.

The concern arises when those protocols become endpoints rather than starting points. A patient with diminished ovarian reserve, for instance, may be funneled into a high-stimulation protocol because it is what the clinic knows and does well, even if emerging evidence suggests that modified minimal stimulation approaches yield comparable or superior outcomes for certain profiles. The protocol that works best for the clinic's average patient is not necessarily the protocol that works best for you.

Patients are rarely told that alternatives exist. Not because clinicians are deliberately withholding information, but because the alternative—explaining the full spectrum of evidence, including its limitations and its applicability to your specific case—requires time that many clinical consultations do not accommodate.

The Success Rate Dilemma

US fertility clinics are required to report outcome data to the Centers for Disease Control and Prevention (CDC) through the Society for Assisted Reproductive Technology (SART). These statistics are publicly accessible and are frequently used by prospective patients to compare clinics. This transparency is valuable. It also creates a perverse incentive.

Clinics motivated to protect their reported success rates may, consciously or not, steer away from patients with poor prognoses or recommend against transfers in cycles where they perceive the odds as unfavorable. A clinic that declines to transfer an embryo it deems suboptimal is protecting its statistics as much as it is protecting the patient. These decisions may be medically sound—but patients deserve to know when statistical considerations are part of the calculus.

Conversely, some clinics may recommend additional cycles when a patient might reasonably be counseled to consider alternatives such as donor eggs, donor embryos, or gestational surrogacy. The conversation about when to pivot is one that should be initiated clearly and compassionately—not indefinitely deferred.

Add-Ons: Where Evidence Ends and Marketing Begins

The fertility industry has seen a proliferation of adjunct services marketed as cycle enhancers. Endometrial scratching, intralipid infusions, growth hormone supplementation, and various immunological interventions have all been offered to patients at premium prices. Some carry a plausible biological rationale. Few have been validated through large, well-controlled randomized trials in the populations most likely to be offered them.

The Human Fertilisation and Embryology Authority (HFEA) in the United Kingdom maintains a publicly accessible traffic-light rating system that categorizes add-ons by their evidence base. No comparable consumer-facing tool exists for US patients, leaving many to navigate these decisions without independent guidance.

When a clinic recommends an add-on service, it is entirely appropriate—and advisable—to ask specifically: What is the evidence base for this intervention in patients with my profile? Is there a randomized controlled trial? What does it show? Your clinic's willingness to engage substantively with these questions is itself informative.

Questions That Create Accountability

None of this is meant to position patients as adversaries of their care teams. The vast majority of reproductive endocrinologists entered this field out of genuine commitment to helping people build families. But the structural incentives described above are real, and informed patients are better positioned to navigate them.

Consider asking your clinic the following:

• What are the alternatives to the protocol you're recommending, and why did you choose this one for my profile specifically?
• Are there less intensive approaches that might be appropriate to try first?
• Which of the recommended add-on services have been evaluated in a randomized controlled trial, and what did those trials find?
• At what point would you recommend we consider changing course—and what would that look like?
• How does your clinic's reporting to SART affect the decisions you make about which patients to treat or which transfers to proceed with?

These are not hostile questions. They are the questions a well-informed patient has every right to ask, and a confident, ethical clinician will welcome them.

Seeking a Second Opinion Is Not Disloyalty

In almost every other area of medicine, second opinions are considered standard practice before major interventions. Oncologists expect them. Orthopedic surgeons expect them. In fertility medicine, however, patients sometimes feel that seeking an outside perspective signals a lack of trust in their provider—or fear that it will damage the relationship.

This reluctance is worth examining. A second opinion from a reproductive endocrinologist at a different institution can surface alternatives you were never offered, challenge assumptions baked into your current protocol, or simply confirm that the plan you are following is indeed the right one. Any of these outcomes is valuable.

Organizations such as RESOLVE: The National Infertility Association offer resources to help patients navigate the US fertility landscape, including guidance on how to evaluate clinics and advocate for themselves within the system.

The Informed Patient as Active Participant

Reproductive medicine is advancing rapidly. The gap between what is known in research settings and what is routinely offered in clinical practice is real and often significant. Patients who read widely, ask specific questions, and treat their consultation as a dialogue rather than a briefing are more likely to receive care that is genuinely individualized.

Your fertility journey belongs to you. The clinic is a partner in that journey—an essential one, with expertise and resources you cannot replicate on your own. But partnership implies mutual accountability. Understanding the forces that shape the options you are offered is not cynicism. It is the foundation of truly informed consent.